SCHEMBL805908

SCHEMBL805908

Fc1ccc(Oc2ccc(Br)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.58
SOS1 Q07889 1/20 0.48
HSPB1 P04792 1/20 0.48
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SCN4A P35499 2/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
MMP2 P08253 2/20 0.42
MMP9 P14780 2/20 0.42
CYP2A6 P11509 1/20 0.42
LTA4H P09960 3/20 0.41
GAA P10253 1/20 0.41
CA2 P00918 1/20 0.40
MMP8 P22894 1/20 0.40
MMP14 P50281 1/20 0.40
CA9 Q16790 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL391385 0.86 MAPT (0.74) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3843978 0.86 MAPT (0.74) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL3842527 0.86 MAPT (0.74) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL6289867 0.86 SOS1 (0.58) SOS1HSPB1MEN1KMT2ALMNA
SCHEMBL351854 0.86 SOS1 (0.58) SOS1HSPB1MEN1KMT2ALMNA
SCHEMBL6290683 0.86 SOS1 (0.58) SOS1HSPB1MEN1KMT2ALMNA
SCHEMBL8594205 0.83 HSPB1 (0.44) MAPTSOS1HSPB1MEN1KMT2A
SCHEMBL7367702 0.83 SOS1 (0.56) SOS1HSPB1MEN1KMT2ALMNA
Phosphine SCHEMBL23732402 0.83 MAPT (0.70) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL1622 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085064-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF KARYOPHARM THERAPEUTICS INC (US) 2026-03-26 US disclosed
US-12384786-B2 Cyclic molecules as Bruton's tyrosine kinase inhibitor MINGHUI PHARMACEUTICAL SHANGHAI LTD (CN) 2025-08-12 US disclosed
US-12331040-B2 Substituted benzofuranyl and benzoxazolyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2025-06-17 US disclosed
CN-111454268-B Cyclic molecules as inhibitors of bruton's tyrosine kinase 明慧医药(上海)有限公司 2023-09-08 CN disclosed
CN-116589465-A Cyclic molecules as inhibitors of bruton's tyrosine kinase 明慧医药(上海)有限公司 2023-08-15 CN disclosed
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-10 US disclosed
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-10 US disclosed
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-10 US disclosed
WO-2023122778-A1 PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES, INC. (US) 2023-06-29 WO disclosed
EP-4180432-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR Sichuan Haisco Pharmaceutical Co., Ltd. (CN) 2023-05-17 EP disclosed
US-6242654-B1 REACTING A PHENOLATE COMPOUND WITH AN ORGANIC FLUORINATING AGENT TO PREPARE A FLUORINE SUBSTITUTED AROMATIC COMPOUND MITSUI CHEMICALS, INC. (JP) 2001-06-05 US disclosed
WO-2000057877-A1 ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2000-10-05 WO disclosed
EP-1013629-A1 Preparation process of fluorine subsituted aromatic compound Mitsui Chemicals, Inc. (JP) 2000-06-28 EP disclosed
EP-0867183-A1 ARYLPIPERIDINOL AND ARYLPIPERIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME SUNTORY LIMITED (JP) 1998-09-30 EP disclosed
US-5276037-A Antiinflammatory agents, antiallergens IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-01-04 US disclosed
US-5272173-A 5-lipoxygenase inhibitors IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-12-21 US disclosed
US-5225438-A Lipoxygenase inhibitors for antiinflammatory agents or antiallergens IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-07-06 US disclosed
EP-0488602-A1 Aryl derivatives ZENECA LIMITED (GB) 1992-06-03 EP disclosed
US-4098908-A PHENOXYPHENYL PYRIDYL KETONES AND DERIVATIVES AND THEIR USE AS HYPOLEPIDEMIC AGENTS SANDOZ, INC. (US) 1978-07-04 US disclosed
US-4031233-A HYPOLIPIDEMIC AGENTS SANDOZ, INC. (US) 1977-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384786-B2 Cyclic molecules as Bruton's tyrosine kinase inhibitor ABL1, BTK, LYN MAPT 4070/4885SOS1 489/4885HSPB1 2018/4885
US-12331040-B2 Substituted benzofuranyl and benzoxazolyl compounds and uses thereof BCL6, MALT1, BTK MAPT 3720/4885SOS1 2568/4885HSPB1 3389/4885
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR BTK, WEE1, WEE2 MAPT 4619/4885SOS1 1299/4885HSPB1 4328/4885
US-20260085064-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF BCL6, MALT1, BCL6B MAPT 676/4885SOS1 2522/4885HSPB1 1224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.